Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

Trial Identifier: FBP00001
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: November 2019
Primary Completion Date: February 2020
Study Completion Date: February 2020
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
UNITED STATES, Florida Hollywood, Florida, UNITED STATES, 33024
UNITED STATES, New York Rochester, New York, UNITED STATES, 14609
UNITED STATES, South Carolina North Charleston, South Carolina, UNITED STATES, 29405